CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIR
The market is up 1.6% over the last week and has risen 22% over the last 12 months, with earnings forecast to grow by 15% annually. In this thriving environment, identifying high growth tech stocks that align with these positive trends can be crucial for investors looking to capitalize on robust market conditions.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...